Round Rock Advisors’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-3,538
Closed -$204K – 309
2026
Q2
$204K Hold
3,538
– – 0.03% 316
2026
Q1
$215K Buy
+3,538
New +$206K 0.03% 306
2025
Q2
– Sell
-3,618
Closed -$221K – 220
2025
Q1
$221K Buy
3,618
+57
+2% +$3.32K 0.04% 196
2024
Q4
$201K Buy
+3,561
New +$199K 0.04% 207
2023
Q1
– Sell
-5,713
Closed -$411K – 146
2022
Q4
$411K Buy
5,713
+969
+20% +$73.1K 0.17% 94
2022
Q3
$333K Hold
4,744
– – 0.15% 98
2022
Q2
$365K Buy
+4,744
New +$361K 0.16% 92

Other funds holding BMY

Round Rock Advisors's BMY Position: Q3 2026 in Review

Round Rock Advisors sold out of Bristol-Myers Squibb (BMY) in Q3 2026, closing a stake of 3,538 shares — an estimated $204K sold.

Round Rock Advisors first reported a position in BMY in Q2 2022 and held it in 7 quarters. The position peaked at $411K in Q4 2022. 2,567 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

  • Round Rock Advisors reported no remaining Bristol-Myers Squibb position as of Q3 2026 after selling out during the quarter.
  • Round Rock Advisors sold 3,538 Bristol-Myers Squibb shares in Q3 2026, an estimated $204K.
  • Round Rock Advisors first reported a position in Bristol-Myers Squibb in Q2 2022 and held it in 7 quarters.
  • Round Rock Advisors's Bristol-Myers Squibb position peaked at $411K in Q4 2022.
  • 2,567 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on Round Rock Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.